机译:Doxorubicin Plus evofosfamide与多柔比蛋白单独在局部先进,不可切除或转移软组织Sarcoma(Th CR-406 / SARC021):国际,多方形,开放标签,随机阶段3试验
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10065 USA;
Allami Egeszsegugyi Kozpont State Hlth Ctr Budapest Hungary;
Washington Univ Sch Med St Louis MO USA;
Mayo Clin Florida Jacksonville FL USA;
Stanford Univ Dept Med Div Oncol Stanford CA USA;
Univ Washington Ctr Canc Seattle Canc Care Alliance Seattle WA 98195 USA;
Univ Michigan Ctr Canc Ann Arbor MI 48109 USA;
H Lee Moffitt Canc Ctr &
Res Inst Tampa FL USA;
Sarcoma Oncol Ctr Santa Monica CA USA;
Duke Univ Ctr Med Durham NC USA;
Herlev Hosp Herlev Denmark;
Inst Bergonie Bordeaux France;
Ctr Leon Berard Lyon France;
Univ Klinikum Mannheim Mannheim Germany;
Presidio Ospedal Candiolo IRCC Turin Italy;
Univ Arizona Ctr Canc Seattle WA USA;
Mayo Clin Rochester MN USA;
Northwestern Univ Robert H Lurie Comprehens Canc Ctr Chicago IL 60611 USA;
Emory Univ Winship Canc Ctr Atlanta GA 30322 USA;
Oregon Hlth &
Sci Univ Portland OR 97201 USA;
McGill Univ Dept Oncol Montreal PQ Canada;
ICO Hosp Duran &
Reynals Barcelona Spain;
Cleveland Clin Fdn 9500 Euclid Ave Cleveland OH 44195 USA;
Univ Pittsburgh Ctr Med Houston TX USA;
Threshold Pharmaceut San Francisco CA USA;
Threshold Pharmaceut San Francisco CA USA;
Sarcoma Alliance Res Collaborat Ann Arbor MI USA;
UZ Leuven Campus Gasthuisberg Leuven Belgium;
机译:Doxorubicin Plus evofosfamide与多柔比霉素单独在局部先进,不可切除或转移性组织Sarcoma(Th CR-406 / SARC021):国际,多期中心,开放标签,随机阶段3试验(Vol 18,PG 1089,2017)
机译:Doxorubicin Plus evofosfamide与多柔比蛋白单独在局部先进,不可切除或转移软组织Sarcoma(Th CR-406 / SARC021):国际,多方形,开放标签,随机阶段3试验
机译:Doxorubicin Plus evofosfamide与多柔比蛋白单独在局部先进,不可切除或转移软组织Sarcoma(Th CR-406 / SARC021):国际,多方形,开放标签,随机阶段3试验
机译:脂质体阿霉素与紫杉醇在治疗晚期艾滋病相关的卡波西斯肉瘤中的成本效益。
机译:吉西他滨和多西他赛与阿霉素相比在先前未经治疗的晚期不可切除或转移性软组织肉瘤(GeDDiS)中作为一线治疗:一项随机对照的3期试验
机译:吉西他滨和多西紫杉醇与多柔比星作为先前未治疗的晚期不可切除或转移性软组织肉瘤(GeDDis)的一线治疗:随机对照3期试验。